Table 1.

Demographic and disease-related characteristics of survey participants.

	Number of participants
Total	438
Female (%)	366 (83.6%)
Age (median; range)	51; range 18-82
Age < 55 years old	239 (66.2%)
Diagnosis
NMOSD MOGAD Transverse myelitis Recurrent optic neuritis Isolated optic neuritis ADEM	242 (55.3%) 99 (22.6%) 79 (18%) 11 (2.5%) 1 (0.3%) 6 (1.4%)
Country of residency
USA United Kingdom Canada Australia France Ireland Israel Austria Egypt Finland Honduras New Zealand Germany Denmark Greece Poland Switzerland United Arab Emirates	367 (83.8%) 37 (8.5%) 10 (2.3%) 6 (1.4%) 3 (0.6%) 2 (0.4%) 2 (0.4%) 1 (0.2%) 1 (0.2%) 1 (0.2%) 1 (0.2%) 1 (0.2%) 1 (0.2%) 1 (0.2%) 1 (0.2%) 1 (0.2%) 1 (0.2%) 1 (0.2%)
Race/ethnicity*
White Hispanic/Latino Black/African American Asian First/Native/Indigenous people Hawaiian/Pacific islander Other	330 (75.3%) 28 (6.4%) 16 (3.6%) 9 (2%) 3 (0.6%) 2 (0.4%) 7 (1.6%)
Associated comorbidities	120 (27.4%) ⁎⁎
Lung disease Diabetes mellitus Hypertension Malignancy Heart disease	49 (11.2%) 22 (5.1%) 19 (4.4%) 17 (3.9%) 13 (3%)
Treated with immunotherapy	354 (80.1%)
Rituximab Mycophenolate mofetil Oral corticosteroids IVIG Azathioprine Eculizumab Tocilizumab Hydroxychloroquine Satralizumab Methotrexate PLEX Inebilizumab	172 (48.6%) 41 (11.5%) 33 (9.3%) 27 (7.6%) 21 (5.9%) 17 (4.8%) 7 (1.9%) 7 (1.9%) 6 (1.6%) 4 (1.2%) 4 (1.2%) 2 (0.6%)
Other	15 (4.3%)
Ocrelizumab SCIG Ravulizumab IVMP 1 g every 4 weeks Tofacitinib	10 (2.8%) 2 (0.6%) 1 (0.03%) 1 (0.03%) 1 (0.03%)

NMOSD = Neuromyelitis optica spectrum disorder

MOGAD = MOG-antibody disease

ADEM = Acute demyelinating encephalomyelitis

IVIG = Intravenous immunoglobulins

SCIG = Subcutaneous immunoglobulins

PLEX = Plasma exchange

IVMP = Intravenous methylprednisolone

^⁎Some participants did not report their race/ethnicity

^⁎⁎Some participants reported more than one associated comorbidity